JP6148664B2 - 眼科治療 - Google Patents

眼科治療 Download PDF

Info

Publication number
JP6148664B2
JP6148664B2 JP2014503208A JP2014503208A JP6148664B2 JP 6148664 B2 JP6148664 B2 JP 6148664B2 JP 2014503208 A JP2014503208 A JP 2014503208A JP 2014503208 A JP2014503208 A JP 2014503208A JP 6148664 B2 JP6148664 B2 JP 6148664B2
Authority
JP
Japan
Prior art keywords
eye
composition
aqueous composition
tramadol
topical administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014503208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513073A (ja
JP2014513073A5 (https=
Inventor
シャーマ，アナント
Original Assignee
オプトソルヴ リサーチ アンド ディベロップメント リミテッド
オプトソルヴ リサーチ アンド ディベロップメント リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105732.0A external-priority patent/GB201105732D0/en
Priority claimed from GBGB1105731.2A external-priority patent/GB201105731D0/en
Application filed by オプトソルヴ リサーチ アンド ディベロップメント リミテッド, オプトソルヴ リサーチ アンド ディベロップメント リミテッド filed Critical オプトソルヴ リサーチ アンド ディベロップメント リミテッド
Publication of JP2014513073A publication Critical patent/JP2014513073A/ja
Publication of JP2014513073A5 publication Critical patent/JP2014513073A5/ja
Application granted granted Critical
Publication of JP6148664B2 publication Critical patent/JP6148664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014503208A 2011-04-05 2012-04-05 眼科治療 Active JP6148664B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1105731.2 2011-04-05
GB1105732.0 2011-04-05
GBGB1105732.0A GB201105732D0 (en) 2011-04-05 2011-04-05 Ophthalmic lubricants
GBGB1105731.2A GB201105731D0 (en) 2011-04-05 2011-04-05 Topical analgesics
PCT/GB2012/000330 WO2012136969A2 (en) 2011-04-05 2012-04-05 Ophthalmic treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017043172A Division JP6419876B2 (ja) 2011-04-05 2017-03-07 眼科治療

Publications (3)

Publication Number Publication Date
JP2014513073A JP2014513073A (ja) 2014-05-29
JP2014513073A5 JP2014513073A5 (https=) 2015-05-28
JP6148664B2 true JP6148664B2 (ja) 2017-06-14

Family

ID=46086008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014503208A Active JP6148664B2 (ja) 2011-04-05 2012-04-05 眼科治療
JP2017043172A Active JP6419876B2 (ja) 2011-04-05 2017-03-07 眼科治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017043172A Active JP6419876B2 (ja) 2011-04-05 2017-03-07 眼科治療

Country Status (12)

Country Link
US (2) US20140088199A1 (https=)
EP (2) EP3799866A1 (https=)
JP (2) JP6148664B2 (https=)
KR (2) KR102165246B1 (https=)
CN (2) CN103687594A (https=)
BR (1) BR112013025493A2 (https=)
CA (1) CA2869280C (https=)
ES (1) ES2836808T3 (https=)
HK (1) HK1254720A1 (https=)
MA (1) MA35070B1 (https=)
MX (1) MX346312B (https=)
WO (1) WO2012136969A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141243A (ja) * 2011-04-05 2017-08-17 オプトソルヴ リサーチ アンド ディベロップメント リミテッド 眼科治療

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201217522D0 (en) * 2012-10-01 2012-11-14 Sharma Anant ophthalmic therapy
GB2516138C (en) * 2013-04-09 2015-12-09 Cresset Biomolecular Discovery Ltd The treatment of inflammatory disorders
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
EP3091985B1 (en) * 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandins for topical use in the treatment of migraines.
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
MX2017010544A (es) * 2015-02-24 2018-06-18 Univ Illinois Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
ES2604816B1 (es) * 2015-09-09 2018-01-29 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
ES2871199T3 (es) * 2015-09-24 2021-10-28 Matrix Biology Inst Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas
CN108697665A (zh) * 2015-09-30 2018-10-23 乔治·爱德华·霍格 局部镇痛性疼痛缓解制剂、其制备和使用方法
CN105232449B (zh) * 2015-10-30 2019-04-09 上海昊海生物科技股份有限公司 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法
WO2018071619A1 (en) * 2016-10-12 2018-04-19 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
WO2018212846A1 (en) 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
PL3634415T3 (pl) * 2017-06-08 2026-04-07 Eye Therapies, Llc Kompozycje okulistyczne zawierające brymonidynę i ketotifen do zastosowania w leczeniu alergii
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
MX2018003456A (es) 2017-12-21 2019-09-06 Gruenenthal Gmbh Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
CN111886001A (zh) * 2018-03-13 2020-11-03 参天制药株式会社 滴眼型洗眼药用组合物
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
WO2021018750A1 (en) 2019-07-26 2021-02-04 Proqr Therapeutics Ii B.V. Ophthalmic compositions comprising viscosifying polymers and nucleic acids
US11504269B2 (en) 2019-11-19 2022-11-22 Jennifer L. Fabian Therapeutic bra
US20230077811A1 (en) * 2020-02-11 2023-03-16 Tufts Medical Center, Inc. Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
WO2021216909A1 (en) * 2020-04-23 2021-10-28 Okogen, Inc. Treatment of viral conjunctivitis
CN112007028A (zh) * 2020-09-03 2020-12-01 北京博纳致恒科技有限责任公司 一种复合睫状肌松弛剂的人工泪液及用途
WO2022183051A1 (en) * 2021-02-26 2022-09-01 Vyluma Inc. Methods and formulations for topical administration of gabapentinoids
WO2023285878A1 (en) * 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
WO2024010039A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物
JPWO2024010045A1 (https=) * 2022-07-06 2024-01-11
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
JPWO2024010040A1 (https=) * 2022-07-06 2024-01-11
WO2025146828A1 (ja) * 2024-01-05 2025-07-10 ロート製薬株式会社 眼科組成物
WO2025159099A1 (ja) * 2024-01-24 2025-07-31 国立大学法人北海道大学 医薬組成物、眼瞼けいれん処置薬、知覚過敏またはジストニア処置薬、および症状モデルマウス

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384043B1 (en) 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
ES2174337T3 (es) * 1996-12-16 2002-11-01 Alcon Lab Inc Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
JP2004143157A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 点眼剤
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
EP1611877A1 (en) * 2004-06-28 2006-01-04 Universidade de Coimbra Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
WO2008153746A1 (en) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
WO2012136969A2 (en) * 2011-04-05 2012-10-11 Anant Sharma Ophthalmic treatments

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141243A (ja) * 2011-04-05 2017-08-17 オプトソルヴ リサーチ アンド ディベロップメント リミテッド 眼科治療

Also Published As

Publication number Publication date
EP3799866A1 (en) 2021-04-07
JP6419876B2 (ja) 2018-11-07
BR112013025493A2 (pt) 2017-03-01
CA2869280A1 (en) 2012-10-11
WO2012136969A3 (en) 2013-01-03
US20160199320A1 (en) 2016-07-14
JP2014513073A (ja) 2014-05-29
US9913813B2 (en) 2018-03-13
CN107982211A (zh) 2018-05-04
MX2013011314A (es) 2014-03-27
MA35070B1 (fr) 2014-04-03
KR102165246B1 (ko) 2020-10-13
WO2012136969A2 (en) 2012-10-11
JP2017141243A (ja) 2017-08-17
ES2836808T3 (es) 2021-06-28
KR20140145948A (ko) 2014-12-24
KR20190004815A (ko) 2019-01-14
MX346312B (es) 2017-03-15
HK1254720A1 (zh) 2019-07-26
EP2694048B1 (en) 2020-10-07
EP2694048A2 (en) 2014-02-12
CA2869280C (en) 2020-03-10
US20140088199A1 (en) 2014-03-27
CN103687594A (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
JP6419876B2 (ja) 眼科治療
ES2812532T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir la rosácea
CA2810537C (en) Compositions for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
JP2014513073A5 (https=)
MX2009000885A (es) Soluciones oftalmicas.
JP2009501726A (ja) 眼科学的活性剤の製剤とその投与の方法
CN101977595A (zh) 用于治疗以及预防眼睑肿胀的组合物
Maggs OCULAR PHARMACOLOGY AND
AU2018372185B2 (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
MX2014006804A (es) Administración eficiente de lipidos a la pelicula lagrimal humana mediante el uso de un sistema de emulsión sensible a la sal.
JP2001519394A (ja) 緑内障の局所治療用フルナリジンの使用法
JP2024528694A (ja) ビンポセチンを用いる近視の治療方法
KR20230098630A (ko) 노안의 예방, 제어 및 근절에 효과적인 저농도 투여량의 상승적 안과 조성물
Hughes et al. Ocular surface anatomy and physiology: impact on product development
CN101780076A (zh) 一种含有他克莫司的药物组合物用于干眼症治疗的用途
RU2772357C2 (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
US20230064711A1 (en) Compositions, kits and methods for enhancing therapeutic compliance
JP2021517139A (ja) 選択的ｓｙｋ阻害剤の使用方法および医薬組成物
ANTIINFLAMMATORY et al. THERAPEUTIC FORMULATIONS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150406

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170307

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170519

R150 Certificate of patent or registration of utility model

Ref document number: 6148664

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250